Monday, April 22, 2024
spot_img

Human trials may reveal efficacy of new Rs 100 cancer pill: Docs

Date:

Share post:

spot_img
spot_img

Shillong, February 29: Only human trials will help understand the efficacy of the new Rs 100 pill developed to prevent recurrence of cancer, said doctors on Wednesday.

According to a report by NDTV, researchers at the Tata Memorial Centre (TMC) in Mumbai claimed to have discovered a treatment to prevent relapse of cancer that would cost only Rs 100.

The study on mice showed that the pill, named ‘R+Cu’, containing a pro-oxidant combination of resveratrol and copper, generated oxygen radicals in the stomach to curb cancer recurrence.

The experimental mice study “is not a substitute for established treatments, which continue to result in cures in a substantial proportion of cancer patients,” Dr Shyam Aggarwal, Chairman, Department of Medical Oncology, at Sir Ganga Ram Hospital told IANS.

In a post on X, Dr. Rajeev Jayadevan, Co-Chairman National IMA Covid Task Force called it “an exaggerated claim”. While calling the research “interesting, praiseworthy”, he said it cannot be seen as “cancer cure.”

Dr Shyam Aggarwal explained that the research shows the effect of cell-free chromatin (fragments of chromosomes released from cancer cells after chemotherapy) on normal tissues causing a cascade of inflammation leading to side effects such as mucositis, low blood counts, etc.

“Use of a combination of copper and resveratrol (a commercially-available nutraceutical) has been shown to degrade circulating cell-free chromatin, leading to reduction of toxicity in some human studies. Other human studies are underway,” he said.

The study claims that the pill can halve the side effects caused by chemotherapy, while also reducing the odds of getting cancer by 30 per cent.

The researchers “used a pro-oxidant combination of copper and resveratrol (found in peanuts, cocoa, grapes) known to damage DNA by generating oxygen radicals,” Dr. Rajeev Jayadevan wrote in his post on X.

“Whether this will translate into real world outcomes for people with cancer (beyond mice), what toxicities could occur from its pro-oxidant, DNA-damaging effect, is yet to be determined,” he said.

However, Dr. Rahul Bhargava, Principal Director & Chief BMT, Fortis Memorial Research Institute, Gurugram, called it “a great breakthrough in the field of medical research. Indian researchers are creating history. If the drug works, it will be a great benefit for cancer patients.”

“The tablet is promising and shows potential to be effective, but human trials are yet to be completed, which could take about five years,” he told IANS.

The tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI) and is expected to be available in the market by June-July. (IANS)

spot_img
spot_img

Related articles

Doltangni kosako ku·rang on·anina VPP-ni membor saksako ra·gala

SHILLONG: Doltangni kosako social media-o kattarangko seahani gimin Voice of the People’s Party (VPP)-ni membor Avner Medon Pariat-ko...

Kevin Bacon returns to Footloose high school, celebrates film’s 40th anniv

Hollywood actor Kevin Bacon revisited Payson High School, the Utah location where his iconic 1984 movie Footloose was...

Not getting too far ahead of ourselves: Head

New Delhi, April 21: Riding on explosive starts, Sunrisers Hyderabad may have won four games on the bounce...

MI eye revenge against Rajasthan in reverse fixture

Jaipur, April 21: A resurgent Mumbai Indians will need to address their bowling woes as they look to...